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Abstract 
Several pieces of EU legislation regulate the marketing and use of chemical substances. While several regulations, 
including the regulations on Plant Protection Products (PPPR), Biocidal Products (BPR) and Chemicals (REACH), 
include provisions for endocrine disrupting substances (EDs), objective scientific criteria are lacking. In order to 
evaluate the potential health, socio-economic and environmental impacts of applying four different options for 
criteria defining EDs across these pieces of legislation, the Commission initiated an Impact Assessment (IA). This 
IA has been supported by two studies, focusing on (a) selection of substances for the IA and the screening of 
their potential for identification as EDs according to different options for defining criteria for identification of 
endocrine disruptors and (b) the potential impacts of various policy options on health, environment, trade, 
agriculture and socio-economy. This report describes a screening methodology that has been developed by the 
JRC to support the first study which has assessed almost all pesticide and biocide active ingredients and a 
selection of substances falling under REACH, the Cosmetic Products Regulation and the Water Framework 
Directive. This screening methodology is not intended to replace an in-depth risk assessment process, and the 
results obtained are not intended to pre-empt regulatory conclusions that may eventually be made under 
different pieces of EU legislation. 
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Disclaimer 
The present screening methodology was developed in the context of an impact 
assessment to evaluate the impacts associated with options for criteria to identify 
endocrine disruptors under the regulations on plant protection products and biocidal 
products. The methodology was developed for the sole purpose of the screening 
exercise, which needed to be carried out in a limited time using available evidence (since 
no additional testing was performed). 
 
The results obtained by applying the screening methodology, which are published 
separately under a contract for DG SANTE (SANTE/2015/E3/SI2.706218), therefore do 
not constitute evaluations of individual substances to be carried out under the respective 
chemical legislations [in particular, Regulation (EC) No 1107/2009 on plant protection 
products, Regulation (EU) No 528/2012 on biocidal products, Regulation (EC) No 
1907/2006 REACH, Regulation (EC) No 1223/2009 on cosmetic products and the Water 
Framework Directive (EC) No 2000/60] and in no way prejudge future decisions on 
active substances to be taken pursuant to these Regulations. 
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Executive summary 
Several pieces of EU legislation that regulate the marketing and use of substances 
contain specific provisions for endocrine disrupting substances. The regulations on Plant 
Protection Products (PPPR)1 and Biocidal Products (BPR)2 further require the European 
Commission to establish scientific criteria to identify substances with endocrine 
disrupting properties. The European Commission initiated an impact assessment and in 
2014 outlined four policy options for identifying endocrine disruptors (EDs) in the 
corresponding Roadmap (EC, 2014, Defining criteria for identifying Endocrine Disruptors 
in the context of the implementation of the Plant Protection Product Regulation and 
Biocidal Products Regulation). 
The screening methodology described within this report was developed by DG JRC to be 
used in the context of an impact assessment to collect and assess, in a limited amount 
of time, the available evidence regarding endocrine disrupting effects of selected 
substances. It provides guidance for (a) the identification of data sources, (b) the 
selection of relevant data and (c) the data analysis procedure to categorise each 
substance as potential endocrine disruptor or not, including application of a limited 
weight of evidence. The methodology was used to determine which of approximately 600 
substances would be potentially categorised as ED under the following four policy options 
set out in the EC Roadmap.  
 Option 1: Interim criteria, no policy change. Assessment based on the CLP 
classification (as carcinogen category 2 or toxic for reproduction category 2, 
harmonised or proposed) and toxicity to endocrine organs. Outcome of the 
screening is ED or Unclassified. 
 Option 2: Assessment based on the IPCS/WHO definition of an ED (i.e. "an 
exogenous substance or mixture that alters function(s) of the endocrine system 
and consequently causes adverse health effects in an intact organism, or its 
progeny, or (sub)populations"). Outcome of the screening is ED or Unclassified. 
 Option 3: Assessment based on the IPCS/WHO definition of an ED, while 
acknowledging different levels of uncertainty in the data. Outcome is of the 
screening is ED (Cat I), Suspected ED (Cat II), Endocrine active (Cat III) or 
Unclassified. ED under option 2 is equivalent to ED (Cat I) under option 3. 
 Option 4: Assessment based on the IPCS/WHO definition of an ED, but 
incorporating the dose at which the effect occurs (giving a measure of the 
substance potency). Outcome of the screening is ED (if dose is below a certain 
cut-off) or Unclassified. 
All selected substances are currently subject to at least one of the following Regulations 
on Plant Protection Products (PPPR), Biocidal Products (BPR), Chemicals (REACH) or 
Cosmetic Products (CPR) and a few are also listed as priority substances under the 
Water Framework Directive (WFD). Substances were selected according to the criteria 
described in the document "Selection of chemical substances to be screened in the 
context of the IA on criteria to identify endocrine disruptors" published on the DG SANTE 
website3 and in Annex 4 of the impact assessment report. 
                                           
1 Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 
October 2009 concerning the placing of plant protection products on the market 
2 Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 
2012 concerning the making available on the market and use of biocidal products 
3 http://ec.europa.eu/health/endocrine_disruptors/impact_assessment/index_en.htm 
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The screening methodology focuses on humans and wildlife and unless specifically stated 
otherwise, all mammalian toxicity data were regarded as being relevant for both humans 
and mammals in the environment (wildlife). As the understanding regarding the 
disturbance of the endocrine system of many invertebrate species is limited, the effects 
on wildlife were confined to the effects observed in mammals, fish, amphibians and to a 
very limited extent in birds and reptiles.  
In addition, this methodology relies solely on existing data (no additional experimental 
work was performed) and is limited to the effects on the estrogenic, androgenic, thyroid 
and steroidogenesis (EATS) pathways. These pathways are relatively well understood 
and consensus guidance on the interpretation of effects observed in OECD Test 
Guidelines is available from OECD Guidance Document 1504. Perturbations of other non-
EATS pathways - although potentially relevant for ED - were largely beyond the scope of 
this methodology. Human epidemiological data, whilst potentially informative, were not 
included unless already part of a regulatory assessment. In silico data (such as (Q)SAR 
predictions) were also not considered.  
The data used were primarily data already evaluated from existing regulatory 
assessment reports. As the data in these documents have been assessed independently 
by the Member State Competent Authorities, they are assumed to be of high quality and 
relevant by default. This information was supplemented by information gathered from 
specific databases (or the references they provide) and from targeted scientific literature 
searches which focussed on endocrine effects and included non-regulatory studies. 
It is important to emphasise that this screening methodology was not intended to result 
in a full assessment of the selected substances. Existing data on the EATS pathways may 
be scarce for many substances and the available test guidelines do not consider all 
relevant species, pathways, or timeframes of exposure. Moreover, within the time 
constraints of the project it was neither possible to assess in detail the quality of 
individual studies nor to carry out an in-depth weight of evidence assessment across all 
available data for each substance. Due to these limitations, this screening methodology 
is neither equivalent to nor intended to replace an in-depth assessment process as 
usually carried out for regulatory purposes. Hence, the outcome of the screening does 
not pre-empt in any way the formal regulatory conclusions that may eventually be made 
under different pieces of EU legislation.  
 
  
                                           
4 OECD, Guidance Document on standardised test guidelines for evaluating chemicals for 
endocrine disruption, Series on Testing and Assessment No. 150, 2012. 
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1 Background 
Several pieces of EU legislation that regulate the marketing and use of substances 
contain specific provisions for substances that can (potentially) cause adverse effects by 
disrupting the endocrine system, so called endocrine disruptors (EDs). The regulations 
on Plant Protection Products (PPPR)5 and Biocidal Products (BPR)6 further require the 
European Commission (EC) to establish scientific criteria to identify substances with 
endocrine disrupting properties. In addition the 7th Environment Action Programme 7 
states that harmonised hazard-based criteria for the identification of EDs should be 
developed. 
Endocrine disruption encompasses a range of mechanisms incorporating the many 
hormones secreted directly into the circulatory system by the glands of the endocrine 
system and their specific receptors, transport proteins and associated enzymes 
(Kortenkamp et al., 2011). With hormones orchestrating virtually all physiological 
processes, the identification of relevant (in vivo) endpoints that indicate a specific 
perturbation of endocrine processes is challenging. This makes it difficult to identify and 
hence regulate substances that can (potentially) cause adverse effects by disrupting the 
endocrine system, so called endocrine disruptors (EDs).  
The EC carried out an Impact Assessment (IA) to evaluate the health, socio-economic 
and environmental impacts of various options for the criteria and their implementation in 
the legislation as described in an EC roadmap8 (hereafter, the Roadmap). The IA has 
been supported by two studies, focusing on (1) selection of substances and screening of 
their potential to be identified as EDs according to the various options for criteria and (2) 
assessing the potential impacts on health, environment, trade, agriculture, and socio-
economy based on the different criteria and policy options in the Roadmap. 
The Roadmap outlines four policy options for identifying EDs. These options include the 
application of so-called interim criteria as specified in the BPR and the PPPR, as well as 
three options based on the International Programme on Chemical Safety/World Health 
Organisation (IPCS/WHO, 2002) definition (with varying degrees of strength of evidence 
or additional inclusion of elements of hazard characterisation). 
To guide the screening of the substances, the methodology described in this report was 
developed by the Directorate General (DG) JRC under the terms of an Administrative 
Arrangement with DG SANTE. The methodology draws on the JRC Report of the 
Endocrine Disruptors Expert Advisory Group (JRC, 2013), which specifies the key 
scientific issues relevant to the identification and characterisation of endocrine disrupting 
substances. The method was consulted with DGs SANTE, ENV, GROW, SG, and the 
European Food Safety Authority (EFSA) and with the European Chemicals Agency 
(ECHA). The methodology has been applied by an external contractor to DG SANTE to all 
approved pesticide and biocide active ingredients (with a few exceptions as listed in 
Appendix A) and to a selection of substances falling under Registration, Evaluation, 
                                           
5 Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 
October 2009 concerning the placing of plant protection products on the market 
6 Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 
2012 concerning the making available on the market and use of biocidal products 
7
 Decision No 1386/2013/EU of the European Parliament and of the Council of 20 
November 2013  
on a General Union Environment Action Programme to 2020 "Living well, within the 
limits of our planet" 
8  European Commission (2014) Roadmap: Defining criteria for identifying Endocrine 
Disruptors in the context of the implementation of the Plant Protection Product 
Regulation and Biocidal Products Regulation 
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Authorisation and Restriction of Chemicals (REACH) Regulation9, the Cosmetic Products 
Regulation (CPR)10 and the Water Framework Directive (WFD)11. The selection of the 
substances to be screened was made by the DGs SANTE, ENV and GROW and the criteria 
used for the selection are reported in Appendix A. The screening results have served as 
input to assessment and comparison of the impacts of the different policy options on 
substances falling under the PPPR and the BPR. 
A draft methodology was supplied to the contractor at the beginning of the study. The 
methodology was further modified, in consultation with the contractor, during the course 
of the study, particularly with respect to the development of the data summary template 
and on the application of weight of evidence (WoE) analysis considerations. The 
development of this methodology has been an iterative process balancing the need for a 
sound scientific strategy against the need to screen many substances in a limited 
amount of time. The assessment of whether a substance has endocrine disrupting 
properties in humans or wildlife populations was based only on existing data. For the 
purposes of this screening methodology, the endocrine relevant effects were limited to 
effects on the estrogen, androgen, thyroid and steroidogenesis pathways. 
As the screening was conducted in the context of an impact assessment, the 
results do not substitute evaluations of individual substances to be carried out 
under the respective legislations. The screening methodology is neither 
equivalent to nor intended to replace the usual in-depth assessment process 
carried out for regulatory purposes. The results obtained are not intended to 
pre-empt and they do not pre-empt the formal regulatory conclusions that may 
eventually be made under different pieces of EU legislation. 
 
  
                                           
9 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 
December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) 
10 Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 
2009 on cosmetic products 
11  Directive 2000/60/EC of the European Parliament and of the Council of 23 October 2000 
establishing a framework for Community action in the field of water policy 
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2 Scope 
The scope of this document is to describe the screening methodology used in the context 
of an IA to collect and assess the available evidence regarding endocrine disrupting 
effects of selected substances. The aim was to assess in a limited amount of time the 
potential endocrine disrupting properties, based solely on already existing data, of 
approximately 600 selected substances that are subject to one or more of the following 
EU regulations/directives: PPPR, BPR, REACH, CPR and the WFD. For all selected 
substances, based on the evidence collected, it was determined whether they would be 
categorised as ED under four different policy options that are set out in the Roadmap 
(Appendix B).  
The methodology comprises the following sequential steps: 
1) Identification of data sources and data types to be collected from these sources 
2) Collection and storage of data considered relevant to inform on potential 
endocrine disrupting properties of a substance 
3) Analysis of data in order to categorise substances under the four policy options of 
the Roadmap. 
Each step comprises a number of different components. A detailed explanation of each 
step is provided in the following sections. Figure 1 provides a schematic representation 
of the methodology. 
 
 
Figure 1. Schematic representation of the screening methodology to potentially identify which substances 
might be categorised as endocrine disruptors under four policy options. 
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The development of this methodology has been an iterative process balancing the need 
for a sound scientific strategy against the need to screen many substances (about 600) 
in a limited amount of time (about 10 months). This required some pragmatic and 
practical decisions to accommodate the limited timeframe whilst still retaining to the 
extent possible scientific rigour, consistency and transparency. 
Based on the policy options identified in the Roadmap4 (Appendix B) the first step was to 
identify the relevant types of data required under each of the options and to identify the 
sources of these data. Three out of four of the options in the Roadmap (options 2, 3 and 
4) are based on the IPCS/WHO definition (IPCS/WHO, 2002) of an endocrine disrupting 
substance. In option 3 the substances are allocated in one of three categories based on 
the different weight of evidence for fulfilling the IPCS/WHO definition.  
These categories are the following:  
 Endocrine Disruptor (Category I)(equivalent to ED under option 2) 
 Suspected Endocrine Disruptor (Category II) 
 Endocrine active substance (Category III) 
Option 4 introduces, in addition, the concept of potency as an element of hazard 
characterisation. 
The IPCS/WHO definition states that: 
"An endocrine disrupter is an exogenous substance or mixture that 
alters function(s) of the endocrine system and consequently causes 
adverse health effects in an intact organism, or its progeny, or 
(sub)populations"  
In analysing the elements of the definition, it is clear that evidence of alteration of the 
endocrine system, evidence of adverse effects and evidence that the one leads to the 
other are required to draw conclusions on the ED properties of a substance. 
Consequently, in the context of this methodology, there was a need to operationalise 
these terms by further defining them and identifying the sources and types of 
information that are most informative in providing evidence of their occurrence in 
relation to exposure to a specific substance.  
The assessment of whether a substance has endocrine disrupting properties in humans 
or wildlife populations was based only on existing data and focuses solely on the active 
substances for biocides and pesticides and not on the formulations. Unless specifically 
stated otherwise, all mammalian toxicity data was regarded as being relevant for 
humans. In addition, mammalian effects, if population relevant, were also used to assess 
potential for endocrine disruption in wildlife populations. As the understanding regarding 
the disturbance of the endocrine system of invertebrate species is limited, the focus for 
wildlife effects was limited to the effects observed in mammals, fish, amphibians and to 
a limited extent in birds and reptiles. 
The type of data which relates to how an adverse effect arises is described usually as 
either mechanistic or mode of action (MoA) data. Hence an "alteration of the endocrine 
system" leading to an adverse effect could be described as an adverse effect arising 
from an endocrine disrupting MoA or mechanism. The initial focus for test guideline (TG) 
development of mechanistic assays to understand endocrine disruption has been in 
relation to interference with the function of hormones (estrogen and androgen) related 
to sexual development and fertility as well as production of these hormones 
(steroidogenesis) and, to a certain extent, disruption of the action of thyroid hormones. 
Consequently, there is a relatively good mechanistic understanding on how perturbations 
of the Estrogenic, Androgenic, Thyroid and Steroidogenesis (EATS) pathways may lead 
to certain adverse effects.  
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Relevant TGs and standardised test methods have been incorporated into the 
Organisation for Economic Co-operation and Development's (OECD) Conceptual 
Framework (OECD, 2012a) for the testing and assessment of endocrine disrupters which 
organises the tests (including non-test information) in five levels according to the type of 
information that the tests provide. The OECD Guidance Document (GD) 150 (OECD, 
2012b) focuses on interpretation of these (draft) TGs with respect to adverse effects 
which may be caused by disruption of EATS pathways as well as the available in vivo and 
in vitro mechanistic assays which inform on disruption of EATS pathways. 
Consequently, for the purposes of this screening methodology, the endocrine relevant 
effects were limited to effects on the EATS pathways, as these are relatively well 
understood and consensus guidance on the interpretation of effects observed in OECD 
TGs is available from the OECD GD 150. Perturbations of other non-EATS pathways – 
although potentially relevant for ED - were largely beyond the scope of this methodology 
since data are limited and consensus guidance on their interpretation towards endocrine 
disrupting MoA is currently lacking. Human epidemiological data, whilst potentially 
informative, were not included unless already part of a regulatory assessment. In silico 
data (such as (Q)SAR predictions) were also not considered, due to lack of scientific 
consensus on how to select and apply such data. 
It is important to emphasise that this screening methodology was not intended to result 
in a full assessment of the selected substances. Existing data on the EATS pathway may 
be scarce for many substances and the available TGs do not consider all relevant 
species, pathways, or timeframes of exposure. Moreover, within the time constraints of 
the project it was not possible to assess in detail the quality of individual studies nor to 
carry out an in depth WoE assessment across all available data for each substance. Due 
to these limitations, this screening methodology is neither equivalent to nor intended to 
replace an in-depth assessment process as usually carried out for regulatory purposes. 
Hence, the outcome of the screening does not pre-empt in any way the formal 
regulatory conclusions that may eventually be made under different pieces of EU 
legislation. 
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3 Information gathering: data sources, collection and 
organisation 
In order to assess the evidence on the endocrine disrupting potential of a substance 
according to the four policy options in the Roadmap, different types of data were 
needed. This information was extracted from a variety of sources, including regulatory 
documents and scientific literature. After extraction, these data were codified in a 
structured way to support the data analysis in order to categorise each substance under 
the four policy options. Detailed information on the used data sources and data collection 
is provided in section 3.1 and section 3.2 respectively. A schematic representation of this 
process is given in Figure 2. 
 
Figure 2. Schematic representation of the workflow from identification of data sources to data analysis. 
Different types of information are required to categorise a substance into each of the 
four policy options (see Figure 3). For option 1, which is based on the interim criteria, 
information is needed regarding the hazard classification according to the Classification, 
Labelling and Packaging (CLP) Regulation and information on toxicity to endocrine 
organs. For options 2, 3, and 4, which are based on the IPCS/WHO definition 
(IPCS/WHO, 2002) of an endocrine disrupting substance, in vivo and/or in vitro 
mechanistic data (endocrine activity) along with data on adverse effects which may be 
endocrine-mediated (ED Adversity) are required. In addition, data on the presence or 
absence of general overt toxicity (non-ED Adversity) are needed, to be able to judge 
whether observed endocrine effects are possibly a non-specific secondary consequence 
of other toxic effects. A plausible link between the available mechanistic and adverse 
effect data was drawn on the basis of the consensus interpretation in OECD GD 150 
(OECD, 2012b) regarding linkage of each adverse effect to one or more of the EATS 
pathways. In order to apply option 4, the doses/concentrations at which effects were 
first observed (LOAEL/LOEC) are required. In the following sections, a more detailed 
description of the data sources used is given. 
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Figure 3. Types of data required to apply the four policy options in the Roadmap. 
3.1 Data sources 
For the categorisation of substances under the four policy options, the following data 
sources were used. 
3.1.1 Source documents for policy options 1 to 4 
3.1.1.1 EU Regulatory documents 
All compounds subject to this IA fall under the scope of at least one specific EU 
Regulation/Directive (PPPR, BPR, REACH, CPR, WFD) and the relevant regulatory 
documents have been used as the primary source to extract the information relevant for 
this IA. As the data from these documents have been assessed independently (e.g. by 
the Member States Competent Authorities (MSCA), EU Regulatory Agencies, etc.), they 
were assumed to be of high quality and relevant by default and no additional quality 
checks were performed. 
Depending under which EU Regulation a screened substance falls, the (eco)toxicological 
data, mostly obtained from laboratory animals (in vivo), were collected from the 
following regulatory assessment reports: 
 Pesticides (PPPR)12 
o Member State Draft Assessment Report (DAR) or Renewal Assessment 
Report (RAR) (Evaluation by the Rapporteur Member State) and peer 
review (by all Member States) of information supplied by the applicant 
(including scientific literature when available). 
o EFSA conclusion (Peer review of the DAR/RAR by EFSA and all Member 
States). 
o For PPP substances for which the risk assessment had been performed by 
the Commission, the DAR is not publically available in the EFSA website 
and thus was retrieved from the confidential area of the European 
Commission's CIRCABC for PPPs. The Review Report, containing the final 
List of EndPoints, was downloaded from the EU Pesticide Database13. 
  
                                           
12 http://dar.efsa.europa.eu/dar-web/provision 
13 http://ec.europa.eu/sanco_pesticides 
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 Biocides (BPR)14 
o Member State Competent Authority Report (CAR) (Evaluation by the 
Rapporteur Member State and peer review (by all Member States) of 
information supplied by the applicant plus any other information 
considered relevant for the assessment)  
o ECHA Assessment Report (peer review of the CAR by ECHA and all 
Member States) 
o For BP substances for which the CAR was not available in the ECHA 
website this was retrieved from the confidential area of the European 
Commission's CIRCABC for BPs.  
For substances that are both pesticides and biocides, all the above EU regulatory 
documents were used for data collection. For pesticides or biocides that are also REACH 
registered, the REACH registrant's submissions were also consulted. For substances that 
have been selected under the REACH criteria, the regulatory documents were used as 
specified below. 
 REACH 
Apart from the REACH substances already selected owing to their use as pesticides or 
biocides, the selection of further REACH substances was done according to a stepwise 
rationale based on 5 criteria (see Appendix A for more details). Therefore, depending 
under which criterion a REACH substance was selected, the following EU regulatory 
documents were used: 
 Criterion 1: 
 Member State Committee opinions and support documents (available via 
the link to the candidate list)15. 
 Criterion 2: 
 Member State Committee opinions and support documents16. 
 Criterion 3: 
1. From the candidate list, the support document for identification of the 
substance as a substance of very high concern is used17. If no information 
was available, documents from the next step were used. 
2. Background Harmonised Classification and Labelling (CLH) dossier and/or 
the Committee for Risk Assessment (RAC) opinion on the CLH dossier18. If 
no information was available, documents from the next step were used. 
3. Risk Assessment Reports carried out and finalised under the Existing 
Substances Regulation (EEC 793/93)19. If no information was available, 
documents from the next step were used. 
4. Annex XV transitional reports for those substances where the work was 
started under the Regulation 793/93, but not finalised before REACH came 
into force20. 
5. If no information was available from the above sources, the registrants' submissions 
were used. 
                                           
14 http://echa.europa.eu/information-on-chemicals/biocidal-active-substances 
15 http://echa.europa.eu/candidate-list-table 
16 http://echa.europa.eu/role-of-the-member-state-committee-in-the-authorisation-
process/svhc-opinions-of-the-member-state-committee 
17 http://echa.europa.eu/candidate-list-table 
18 http://echa.europa.eu/web/guest/opinions-of-the-committee-for-risk-assessment-on-
proposals-for-harmonised-classification-and-labelling 
19 http://echa.europa.eu/en/information-on-chemicals/information-from-existing-
substances-regulation 
20 http://echa.europa.eu/information-on-chemicals/transitional-measures/annex-xv-
transitional-reports 
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 Criterion 4:  
1. Final background document on a substance adopted by RAC as well as the 
opinion adopted by RAC (both documents are listing study overviews21. If 
the restrictions for substances in question were old ones and therefore no 
information was available, documents from the next step were used. 
2. Risk Assessment Reports carried out and finalised under the Existing 
Substance Regulation (EEC 793/93) 22. If no information was available, 
documents from the next step were used. 
3. Annex XV transitional reports (for those substances where the work was 
started under the Regulation 793/93, but not finalised before REACH came 
into force)23. 
 Criterion 5: 
1. From the Community Rolling Action Plan (CoRAP) list 24 , the following 
documents were used: 
2. In case the process to evaluate substance under CoRAP had been 
concluded, then the available dossier was used. 
3. In case the process had not been concluded (most cases), the 
documents/presentations/factsheets prepared by the MSCA and presented 
to ECHA Endocrine Disruptor Expert Group (ED EG) were used if available 
and not containing potentially confidential information. 
4. In case no MSCA document was available the registrants' submissions 
were used. 
 Cosmetics (CPR) 
o Opinions of Scientific Committee on Consumer Safety, SCCS25 were used. 
 Water Framework Directive (WFD) 
o No additional sources were used for the data collection of substances 
regulated under the WFD since these substances were already subject to 
one of the other legislative frameworks (PPPR, BPR, REACH or CPR) and 
the regulatory documents available from these other regulatory 
frameworks listed above were used.  
In specific cases documents (peer reviewed Opinions) identified in the EFSA website 
have been used (e.g. for substances which are also considered food contaminants). 
3.1.1.2 EU Additional sources 
In addition, data were collected from the following sources, focusing on endocrine effects 
(particularly as a source of mechanistic data) including non-regulatory studies: 
 ToxCast: US Environmental Protection Agency (EPA) database: Selection of 
ED relevant in vitro assay data related to estrogen, androgen- and thyroid-
receptor and steroidogenesis (see Appendix C for more details). 
 ToxCast ER (Estrogen Receptor) prediction model. Computational model that 
integrates results from 18 estrogen receptor ToxCast high-throughput 
screening assays, in order to discriminate bioactivity from assay-specific 
interference and cytotoxicity. The model predicted results of EDSP Tier 1 
guideline and other uterotrophic studies with 84% to 100% accuracy (Browne 
et al., 2015). Prediction values of individual substances, where available, were 
                                           
21 http://echa.europa.eu/previous-consultations-on-restriction-proposals 
22 http://echa.europa.eu/en/information-on-chemicals/information-from-existing-
substances-regulation 
23 http://echa.europa.eu/information-on-chemicals/transitional-measures/annex-xv-
transitional-reports 
24  http://echa.europa.eu/information-on-chemicals/evaluation/community-rolling-action-
plan/corap-table 
25 http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm) 
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kindly provided by the US EPA. In case the result of the ToxCast ER prediction 
model was not available for a certain substance, then the individual ToxCast 
in vitro assays related to the estrogen receptor were used as indicated in the 
previous bullet point (see Appendix C for more details). 
 Endocrine Disruptor Screening Program (EDSP) (US EPA) WoE analyses 
(summarised data) of ED relevant in vitro and in vivo assays, focusing on 
EATS pathways. The analysis is based on data from the current registration 
documents, scientific literature and additional ED relevant tests that were 
performed specifically for the EDSP. 
When substances were present in any of the following sources, the mentioned references 
were used for data collection:  
 JRC's Endocrine Active Substances Information System (EASIS) 
 The Endocrine Disruption Exchange (TEDX) 
 Substitute It Now (SIN): List of substances identified by the non-
governmental organisation ChemSec as Substances of Very High Concern, 
specifically substances listed because of ED concerns, including their 
evaluation by the Danish Centre on Endocrine Disruptors (Danish Centre on 
Endocrine Disruptors, 2012). 
 Public consultation (JRC, 2015): References supplied by the public 
consultation that were considered. 
An inventory of screened substances was compiled to indicate where substances are 
listed (potentially in more than one source from those listed above) in the EU Regulatory 
documents and additional sources. All relevant sources were used for data collection (as 
shown in figure 4). 
 
 
Figure 4. Example of inventory of substances screened with indication of the available data-sources for each 
substance. 
 
3.1.1.3 Scientific literature 
In the case of substances not appearing in any of the above-mentioned 'additional 
sources' a search of the open literature (limited to publications in English) was 
performed by using both the following search-engine tools: 
 SCOPUS: querying compound name & endocrine 
 SciFinder: querying "endocrine disruption" & substance identifier based on 
CAS RN 
All references were further screened for relevance, e.g. removing invertebrate studies 
which are not within the scope of this screening methodology. Only studies that have 
been performed using single substances (or the active ingredient in the case of PPPs and 
BPs) were considered: formulations were beyond the scope of this screening exercise. In 
the case of more than 50 references per substance a pragmatic approach was applied to 
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identify the most pertinent focussing on the most recent (e.g. published after most 
recent EU regulatory assessment). Considering time constraints, literature searching was 
only performed on pesticides and biocides. 
All data obtained from the additional sources and literature searching were considered to 
be reliable by default, unless there were clear indications to the contrary. Thus, no 
additional systematic quality check was performed on these data. Data from these 
databases and the published scientific literature gathered in the targeted searches are 
considered valuable because they are specifically designed to investigate whether a 
substance has activity towards the endocrine system (EATS pathways). 
3.1.2 Additional source documents for policy option 1 
The categorisation of a substance as ED under Option 1 is based on the interim criteria 
set out in the PPPR (article 3.6.5) and BPR (article 5[3]): 
 substances that are or have to be classified as carcinogenic category 2 and 
toxic for reproduction category 2, shall be considered to have endocrine 
disrupting properties. 
 substances such as those that are or have to be classified as toxic for 
reproduction category 2 and which have toxic effects on the endocrine organs, 
may be considered to have such endocrine disrupting properties. 
Therefore, the additional sources used to categorise substances under policy option 1 are 
EU regulatory documents where information on hazard classification is available. 
Particularly, both harmonised classification (when available) and the proposed 
classification (when relevant) were considered and the sources used were:  
 For the harmonised classification 
o classification as included in Annex VI of Regulation (EC) 1272/2008 (CLP 
Regulation) 26 , which is available in the C&L inventory of the ECHA 
website27; 
 For the proposed classification (when the proposal was more recent than the 
decision for the harmonised C&L or no harmonised classification was available) 
o classification proposal concluded during the peer review process under 
PPPR (EFSA Conclusion or DAR/RAR) and/or under BPR (ECHA Assessment 
Report/CAR).  
o Background Harmonised Classification and Labelling (CLH) dossier and/or 
the Committee for Risk Assessment (RAC) opinion on the CLH dossier28 
when the proposal has not been yet adopted. 
o Classification proposed in the regulatory documents (when available) for 
miscellaneous chemicals (e.g. Member State Committee Opinions).  
o REACH Registrant’s proposal where relevant. 
For option 1, together with CLP classification, also information on the toxicity to 
endocrine organs is required which was obtained from the data sources described in 
Section 3.1.1.  
  
                                           
26 Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 
December 2008 on classification, labelling and packaging of substances and mixtures 
27 http://echa.europa.eu/web/guest/information-on-chemicals/cl-inventory-database 
28 (http://echa.europa.eu/web/guest/opinions-of-the-committee-for-risk-assessment-on-
proposals-for-harmonised-classification-and-labelling 
 The screening methodology described in this report was developed in the context of an impact assessment to evaluate the impacts associated with options for criteria to identify 
endocrine disruptors under the regulations on plant protection products and biocidal products. The results obtained by applying the screening methodology, published separately 
under a contract for DG SANTE (SANTE/2015/E3/SI2.706218), do not constitute evaluations of individual substances to be carried out under the respective chemical legislations 
[in particular, Regulation (EC) No 1107/2009 on plant protection products, Regulation (EU) No 528/2012 on biocidal products, Regulation (EC) No 1907/2006 REACH, Regulation 
(EC) No 1223/2009 on cosmetic products and the Water Framework Directive (EC) No 2000/60] and in no way prejudge future decisions on active substances to be taken 
pursuant to these two Regulations. 
15 
 
3.2 Data collection 
In order to categorise all substances under the four policy options, different types of 
data were collected to then capture all relevant information needed to support the 
identification of EDs. Four main categories of data were collected as follows: 
1. General substance information: chemical name; CAS Registry Number; 
current CLP classification; specific remarks in the regulatory source documents 
relevant to ED assessment. 
2. Study information: type of toxicity test (in vitro, in vivo, mammalian, fish, 
amphibians, and to a limited extent birds and reptiles); the study principle, 
including the protocol used (e.g. OECD or US EPA TGs and deviations from these 
guidelines; non-GLP study); the source of the data (e.g. EU regulatory document, 
scientific literature, ToxCast, EASIS, SIN, etc.), including the primary reference 
given within this source and the reporting date. 
3. Study details: test species and strain (for in vitro assays, the test system used 
as cell line, receptor, etc.); number of animals per group: doses administered; 
route and method of administration; duration of exposure; the purity of the 
substance. 
4. Effect details: sex, generation and/or life stage for which the effect was 
observed; the lowest dose/concentration at which the specific effect was 
observed (LOAEL/LOEC), including the direction of the effect (increase, decrease) 
and optional additional details to further specify the observation. In the case of in 
vitro studies, the lowest effect concentration is generally not reported, so 
EC50/AC50/IC50 values derived from the concentration-response relationships 
were captured instead. 
From the data sources listed in section 3.1.1, the relevant effects were collected from 
non-acute toxicity in vivo studies, especially from studies on developmental toxicity, 
reproductive toxicity, carcinogenicity and (sub)acute and (sub)chronic repeated dose 
toxicity. The selection of the effects was primarily based on the OECD GD 150 (OECD, 
2012b), as this document represents a consensus interpretation of the evaluation of 
effects that indicate endocrine pathway interference. OECD GD 150 provides a list of 
effects (in vitro and in vivo) which are related specifically to the EATS pathways. 
Therefore, for this screening methodology, all potentially ED-mediated effects from the 
studies listed in OECD GD 150 were captured from the toxicological study reports. 
Similarly, effects from mechanistic in vivo and in vitro tests, either from the regulatory 
documents or from additional sources (e.g. ToxCast, EASIS, SIN, TEDX, scientific 
literature), were captured as well (more details regarding the selection of tests can be 
found in Appendix C). 
In addition to the EATS-specific effects, some other effects were captured that are not 
directly linked to endocrine disruption, e.g. effects considered to be secondary to general 
toxicity (such as decreased body weight and food consumption, etc.). These endpoints 
are important for the interpretation of the specificity of the potentially endocrine-
mediated effects, especially if they are occurring at the same dose as (or lower than) the 
EATS-specific effects. A complete list of endpoints is included in Appendix D. 
3.3 Data organisation 
All collected data were captured in a template (Excel file), which was specifically 
developed by DG JRC for this screening methodology. Table 1 provides a detailed 
description of the columns of the template. 
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Table 1. Description of the columns of the template. 
Column name Type of 
column 
Column description 
Type of toxicity pick list Type of toxicity study (in vitro, mammalian in vivo or wildlife in 
vivo) 
Study principle pick list The type of protocol used for the toxicity study (e.g. two-
generation study, 90-days repeated dose, etc.) 
Study ID Matrix free text Number to identify study for further data-analysis within this 
methodology 
Study reference ID free text Identification code related to the source used to gather the data 
filled in the template 
Study guideline 
(OECD/US EPA) or 
remarks 
free text The guideline used for the study design, if given (e.g. OECD 416). 
Also other remarks regarding the guideline can be given here 
Source free text Source used for the toxicity data (e.g. EFSA DAR, ECHA database, 
EASIS, ToxCast, etc.) 
Reference (citation) free text Reference given within the source (e.g. the study unique 
identifier, or scientific paper) 
Reporting date free text Reporting date, if available, of when the study was performed. If 
the reference is a scientific paper, this can be the date of 
publishing 
Species pick list Species used for the toxicity study. For in vitro test systems, this 
field can be used to specify the cell system model 
Strain or in vitro model free text The specific strain used for the toxicity study, when applicable. 
Animals/sex/group free text Number of animals used for each dose group 
Sex (administration) pick list Sex of the animals administered in a particular study 
Purity (%) free text Purity of the substance (% of active ingredient) administered 
Route of 
administration 
pick list The route of exposure that is used for exposing the animals (oral, 
inhalation, dermal, direct or other). For in vitro test systems, the 
exposure is normally from the cell medium 
Method of 
administration 
pick list The method that is used to expose the animal to the test 
compound (e.g. feed, gavage, whole-body, capsule, water, 
topical, subcutaneous, intravenous or other) 
Doses tested free text The range of the doses applied within the test or a listing of all 
the individual doses (e.g. 1, 3, 5, 10), excluding the 0 or control 
concentration 
Lowest dose tested free text The lowest dose used within the test (excluding the 0 exposure or 
control) 
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Table 1 (continued). Description of the columns of the template. 
Column name Type of 
column 
Column description 
Highest dose tested free text The highest dose used within the test 
Dose unit pick list The unit for the dose applied in the test 
Duration of exposure free text Duration of exposure 
Duration unit pick list The unit for the duration of exposure 
Generation/Life 
stage 
pick list The generation or life stage for which the reported effect is given 
(e.g. Adult (P1), Foetus, Offspring F1, Offspring F2, Embryo, Egg, 
Larval, etc.) 
Sex (effect dose) pick list The sex for which the observed effect is reported 
Lowest Effect dose free text The actual dose at which the effect is observed. In case for each of 
the doses tested in the study there is a description of effect on a 
particular endpoint, capture only the effect observed at the lowest 
dose since it is assumed that at higher doses the effect is still present 
and possibly more severe. For in vitro assays (e.g. ToxCast) this 
refers to EC50 
Effect type pick list Broad categories of effects defined by the JRC to better organise the 
different effects to be captured in this template. These broader 
categories are: In life observations; organ weight, organ 
histopathology, clinical chemistry, related to reproduction or 
development or abnormalities observed. 
Effect target pick list The specific effect observed (specifying what exactly is targeted from 
the broader categories given above: e.g. which organ, which 
hormone etc.) 
Effect classification pick list Each effect target is grouped in 5 groups: A) in vitro mechanistic, B) 
in vivo mechanistic, C) EATS specific adversity, D) Non-specific 
adversity (may or may not be indicative of EATS) and E) Adversity -
General 
Effect description free text A more detailed description of what is actually observed for a certain 
effect 
Effect determination free text Field to state whether the effect determination (e.g. weight gain) is 
relative or absolute 
Effect direction pick list Indicating whether the observed effect is increased, decreased, or 
not changed 
NOAEL/NOEL/NOEC free text NOAEL/NOEL/NOEC values 
LOAEL/LOEL/LOEC free text LOAEL/LOEL/LOEC values 
Unit pick list The unit of NOAEL/NOEL/NOEC/LOAEL/LOEL/LOEC values 
Additional remarks free text Any relevant remark to assist with data interpretation 
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4 Data analysis 
The data collected and organised in the template were then analysed in order to 
categorise all substances screened under the four policy options. 
Since it was anticipated that the data set might be too limited to allow a conclusion to be 
drawn with respect to ED Cat I, II or III for many substances, an additional category, 
not defined in the Commission Roadmap, of "unclassified" was introduced to categorise 
those substances that either cannot be assessed because there is no data to inform on 
ED properties or where the available data indicate a lack of activity towards the 
endocrine system. The term "unclassified" is used rather than "not ED" considering the 
incomplete coverage of available assays and the possibility that new data generated in 
the future may indicate ED activity (e.g. from other non-EATS endocrine MoAs). The 
additional category "unclassified" has been introduced for all options. 
The workflow to perform the data analysis was different for each option, since each 
requires different types of data to support the categorisation. Therefore, in the following 
sections, the data analysis is described separately depending on whether it was used to 
assess policy option 1 or options 2/3 or option 4. 
4.1 Categorisation under option 1 (ínterim criteria) 
As described in previous section 3.1.2, the categorisation of a substance under option 1 
is first triggered by its classification according to the CLP Regulation, harmonised (when 
available) or proposed (when more recent), as toxic for reproduction Category 2. Then, 
if accompanied also with classification as carcinogen Category 2 no further information is 
required to categorise the substance. If the substance is only classified as toxic for 
reproduction Category 2 then there is the need to evaluate if the substance also causes 
toxicity to endocrine organs. 
Figure 5 provides a schematic representation of the data-analysis process under option 
1. 
 
 
Figure 5. Decision tree leading to categorisation as ED according to the interim criteria as stated in the 
PPPR and the BPR.  
As no definition is given in the interim criteria for which organs should be regarded as 
endocrine organs, for the purpose of this IA, the endocrine organs were considered to be 
the organs that secrete hormones as well as the target organs that express the 
receptors for the sex hormones and thyroid hormones and are included in the OECD GD 
150 (mammary gland; accessory sex glands e.g. Cowper’s gland, seminal vesicles, 
prostate gland, bulbourethral glands, glans penis; testis; epididymis; penis; cervix; 
uterus, endometrium; vagina; hypothalamus; pituitary; thyroid; adrenals; ovaries; 
placenta; levator ani/bulbocavernosus muscles (LABC)). This information is obtained 
from the toxicity data sources that are described in section 3.1.1. 
According to the criteria set out in the CLP Regulation the classification of a substance as 
carcinogenic or toxic for reproduction is only relevant to humans. Therefore, option 1 is 
not applicable to vertebrate wildlife. 
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4.2 Categorisation under options 2 and 3 
In this methodology, about 180 endpoints were selected for data collection covering all 
those listed in the OECD GD 150 and supplemented with some others, which are 
frequently reported in toxicological studies related to systemic toxicity (including body 
weight and food intake), that are informative only in the context of whether potentially 
ED-mediated effects are secondary to other non-ED modes of action (for more details 
refer to section 3.2 and Appendix D).  
As also explained in the OECD GD 150, not all the effects provide the same type of 
information towards supporting if a substance causes an adverse effect through an EATS 
pathway. In fact, some effects are more specific towards EATS pathways while some 
others might provide less specific information which can be relevant only in combination 
with mechanistic data. 
Additionally, among the about 180 endpoints considered in this methodology, some are 
related to in vitro studies and others to in vivo studies. In general, in vitro effects 
provide information on the mechanism through which a substance could potentially 
cause adversity (e.g. binding to a receptor). In vivo effects, instead, provide information 
which is related to the manifestation of adversity (e.g. damage to an organ). In some 
specific toxicological studies, in vivo endpoints can also provide mechanistic information 
(e.g. changes in plasma vitellogenin in fish). 
Therefore the confidence in concluding that a substance is a potential ED increases with 
multiple types of information provided by mechanistic data, apical adverse effects data 
and ultimately by deriving a biologically plausible link between the two (as required to 
fulfil the IPCS/WHO definition). 
In conclusion, the effects collected for a certain substance were evaluated in terms of 
the types of information they provide to support an assessment of ED properties. Figure 
6 shows a schematic representation of the step-wise approach used for the data 
analysis. In the following sections, a more detailed description is provided regarding data 
processing and the application of the decision tree. 
 
 
Figure 6. Stepwise approach used in the data analysis. 
 
4.3 Data processing 
The data processing is based on the grouping of effects (among the 180 endpoints 
selected for the data collection) according to the type of information they provide to 
support whether a substance causes adverse effects via an endocrine MoA. Five groups 
were defined in relation to two components: 1) level of specificity of adverse effects 
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towards EATS pathways based on the interpretation provided in OECD GD 150 and 2) 
mechanistic/mode of action information, which may be generated in vitro or in vivo. 
Figure 7 illustrates these 5 groups (A-E) with a brief description of each. 
 
 
Figure 7. Grouping of types of information for data processing. 
 
A detailed description of each group is as follows: 
A. In vitro mechanistic 
This group captures all in vitro information relevant to EATS pathways collected 
from the selected sources. Examples of in vitro mechanistic information include 
measurements of receptor binding, inhibition of enzyme activity, cellular 
proliferation, or changes in steroid hormones levels in a cell system. 
B. In vivo mechanistic (including in vivo hormone levels) 
This group mainly refers to in vivo assays which are designed to provide 
mechanistic information (towards EATS pathways). For this methodology, as a 
default assumption, the evidence derived from these effects was regarded as 
stronger evidence of an ED MoA, compared to in vitro effects. The reasoning is 
that in vivo mechanistic effects, unlike in vitro methods, incorporates absorption, 
distribution, metabolism and excretion. In addition, effects observed in vivo are 
generally more "downstream" events along the pathway leading to ED adversity 
than in vitro endpoints. Therefore, they are more closely linked to the 
manifestation of the adversity. The following tests according to OECD GD 150 
provide in vivo mechanistic information: Hershberger, uterotrophic, male and 
female pubertal assays, adult male assay, amphibian metamorphosis assay, and 
fish short-term reproduction assay. In addition, some of the other OECD TGs in 
levels 4 & 5 of the OECD Conceptual Framework (OECD, 2012a) provide 
information on both adverse effects and mechanistic information. For example, 
changes in vitellogenin levels in fish assays, as well as changes in in vivo 
hormone levels in mammalian assays can also be regarded as informative on the 
MoA, as they indicate perturbations of specific endocrine pathways. Fluctuations 
in hormone levels can be observed within certain limits without adverse 
consequences, so the changes cannot be considered adverse on their own. The 
point at which these fluctuations become significant cannot be generally defined 
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and would in an actual assessment always require a case-by-case decision which 
goes beyond the scope of this methodology. Therefore, for the purpose of this 
screening methodology, all significant changes in hormone levels were regarded 
as biomarkers informative of a specific MoA. Details on which hormones are 
considered are provided in Appendix D. 
C. EATS specific adversity 
The question of whether an observed effect can be considered adverse requires 
an assessment of data that goes beyond the screening methodology applied here. 
From a practical point of view, it is much easier and straightforward to conclude a 
change in e.g. morphology as directly adverse, without the requirement to assess 
in addition whether the change would actually lead to an impairment of function. 
Consequently, for the purpose of this screening, this group includes all those 
effects which are considered in OECD GD 150 indicative of E, A, T or S pathway. 
All these effects are then considered to be adverse effects. For more details refer 
to Appendix D. 
D. Non-specific adversity (may or may not be indicative of EATS) 
This group refers to the effects that are considered in the OECD GD 150 
potentially indicative of, but not specific to, EATS pathways. Therefore they are 
considered informative only in combination with mechanistic-effects and/or EATS-
specific effects (groups A to C) requiring a case-by-case decision to conclude if 
they can inform on ED properties.  
E. General adversity 
This group refers to in vivo effects which are only related to general systemic 
toxicity (e.g. changes in body weight, food consumption, signs of animal stress, 
mortality, etc.). Therefore these effects do not provide information on endocrine 
disrupting MoA. However, for the purpose of this screening methodology, they 
were collected and analysed to help with the interpretation of how specific the 
adverse effects in groups "C" and "D" are to inform on the likelihood of being 
endocrine-mediated. 
In fact, effects (those grouped above under C and D) that are observed in presence of 
general adversity are considered to arise as a consequence of general toxicity (when the 
whole biological system is perturbed) and therefore, by default for this screening, were 
not considered specific or informative on endocrine disrupting MoA. 
4.3.1 Application of a decision tree with limited WoE analysis 
4.3.1.1 Decision tree 
The next step of the data analysis was to evaluate the collected information organised in 
the five groups (A to E) in order to decide if a substance is a potential ED. 
For groups A to D, it can be asked whether a substance causes any of the effects falling 
in that specific group. Group E (General adversity) is not associated with a question, 
since this group only serves to put the other effects into context (as explained in section 
4.2.1). 
Ultimately, a question was posed regarding the likelihood of a biologically plausible link 
between the adverse effects (groups C and D) and the mechanistic information (groups 
A and B). If so, both adverse effect(s) on the one hand and the mechanistic evidence on 
the other hand should correspond to a disruption of the same pathway, i.e. E, A, T or S. 
Therefore a total of five questions were posed with each of these having two possible 
answers "yes" or "no" (Table 2). 
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Table 2. Questions of the decision tree developed for the data processing for options 2 and 3. The actual 
decision tree is given in figure 8. 
Question Answer 
Is there evidence of adverse effect(s) that may or may not be 
EATS-specific in an intact organism, or its progeny, or in a (sub) 
population? 
Yes / No 
Is there evidence of adverse effect(s) – EATS specific in an 
intact organism, or its progeny, or in a (sub) population? 
Yes / No 
Is there evidence of in vivo mechanistic information? Yes / No 
Is there evidence of in vitro mechanistic information? Yes / No 
Is there evidence of a plausible link between in vitro/in vivo 
mechanistic information and the observed EATS-specific or non-
specific adverse effect(s)? 
Yes / No 
 
Considering the different combinations of answers to the five questions, all the 
possibilities are captured in a decision tree (Figure 8) which allows for a potential 
categorisation, as Cat I, II or III. Substances for which not enough data are available to 
place the substance in any of the aforementioned categories are regarded as being 
unclassified. 
In this decision tree, "EATS specific adversity" is considered as a strong indication of ED 
related adversity, leading to the "higher" potential categorisation of the substances as 
"ED (Cat I) or (Cat II)". In contrast, "Non-specific adversity (may or may not be 
indicative of EATS)" is considered as indication of ED related adversity, which may lead 
to "lower" potential categories, mostly Cat II, III and "Unclassified" in the absence of 
"EATS specific adversity".  
In vivo mechanistic data (which may or may not be supported by in vitro mechanistic 
data) are considered as strong indication of endocrine MoA. In case in vivo mechanistic 
data are available and a plausible link is determined with either "EATS specific adversity" 
or "Non-specific adversity (may or may not be indicative of EATS)" the substance is 
classified as Cat I.  
In vitro mechanistic data, in the absence of in vivo mechanistic data, are generally 
considered as weak indications of endocrine MoA. In this case, a substance could be 
categorised as Cat I, Cat II or Cat III depending on the type of adversity observed (EATS 
specific adversity or non-specific adversity) and on whether or not a plausible link to the 
observed adversity is established. The possibility that a substance is categorised as Cat I 
on the basis of in vitro mechanistic data is limited to the cases where there is clear and 
strong evidence of EATS specific adversity and a plausible link with equally clear and 
strong in vitro mechanistic data is established. However, in applying the decision tree, 
presented in figure 8, it was often difficult to establish a direct plausible link to adverse 
effects and thus a Cat II in case of presence of EATS specific effects or Cat III in 
presence of non-specific adverse effects was more likely. 
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Figure 8. Decision tree leading to the different potential ED classifications according to options 2 and 3. 
Substances that are classified as ED Cat I are considered to be EDs under option 2. 
 
In some cases, a substance can be classified as ED Cat I even if there is only information 
on adversity without mechanistic data available. In these cases, the adverse effects 
observed are considered also indicative of an endocrine disrupting MoA, through EATS 
pathways. Therefore, they are considered to be diagnostic for endocrine disruption. Two 
examples of such effects have been provided by the JRC Report of the Endocrine 
Disrupters Expert Advisory Group (ED EAG) (JRC, 2013): 
 Example 1: "In ecotoxicological assessment a change in sex ratio of fish was seen 
as both adverse and, according to the majority of the experts, highly likely to be 
a marker of endocrine disruption. An example was given of the OECD fish sexual 
development TG (OECD TG 234) in which consistent co-observation of a change 
in sex ratio accompanied by a change in vitellogenin level (biomarker of 
endocrine activity) has been observed in certain fish species (OECD, 2012b). For 
other fish species than those recommended in the TG the basis for using sex ratio 
as diagnostic of endocrine disruption was unclear. The degree of change in sex 
ratio would also be a factor in weighing the strength of evidence as a complete 
feminisation/masculinisation could be considered as diagnostic while only a small 
change or a delay in sexual differentiation might not." 
 Example 2: "In humans a pattern of effects known as testicular dysgenesis 
syndrome including hypospadias, cryptorchidism and decreased sperm quality 
which can also be replicated in laboratory mammals by certain chemicals 
(including hypo- and a-spermatogenesis, atrophy of the seminal vesicles and 
prostate, nipple retention, hypospadias, penis malformations, vaginal pouches, 
ectopic testes and decreased anogenital distance), was seen as highly likely to be 
mediated by an anti-androgenic mode of action." 
 The screening methodology described in this report was developed in the context of an impact assessment to evaluate the impacts associated with options for criteria to identify 
endocrine disruptors under the regulations on plant protection products and biocidal products. The results obtained by applying the screening methodology, published separately 
under a contract for DG SANTE (SANTE/2015/E3/SI2.706218), do not constitute evaluations of individual substances to be carried out under the respective chemical legislations 
[in particular, Regulation (EC) No 1107/2009 on plant protection products, Regulation (EU) No 528/2012 on biocidal products, Regulation (EC) No 1907/2006 REACH, Regulation 
(EC) No 1223/2009 on cosmetic products and the Water Framework Directive (EC) No 2000/60] and in no way prejudge future decisions on active substances to be taken 
pursuant to these two Regulations. 
24 
 
4.3.1.2 Limited WoE analysis 
Although the decision tree (figure 8) leads to only a "yes/no" qualitative answer to the 5 
questions, the strength and WoE available was also considered.  
In general, weight of evidence (WoE) analysis is an approach widely used to support 
decision-making in different scenarios in the field of chemical risk assessment. Several 
guidance documents exist under different regulatory programmes to describe the 
principles of WoE analysis and assist experts in its practical use to support specific 
purposes. However, while the WoE analysis can be a structured and systematic process 
that can rely on a set of clearly defined and prescriptive criteria, the final conclusion can 
still be considered subjective, as it is rather based on expert judgement and expert 
knowledge. Therefore, its practical implementation requires an ad-hoc definition of the 
criteria to be used when applying it within a specific context. Furthermore WoE analysis 
involves an extensive evaluation of all available evidence which is necessarily an 
extensive time demanding process. 
As summarised in the 2013 JRC ED EAG Report (JRC, 2013), WoE analysis is described 
as weighing all available evidence, both positive and negative in order to reach a 
conclusion. Factors that are identified as important include quality, reliability and 
relevance of the individual studies as well as the consistency and reproducibility of 
reported effects, the pattern of effects across and within studies, number of species 
showing the same or similar effects, time of onset of effects and life stage affected, 
dose-concentration dependence and the biological plausibility of a causal relationship 
between the induced endocrine activity and the adverse effect(s). Concerning specifically 
study reliability, the report states that quality criteria are necessary to accept the validity 
of reported findings, referring to the approach described by Klimisch et al. (1997). The 
report goes on to propose that whilst recognising the value of studies conducted 
according to OECD TGs (or equivalent) non-guideline data (e.g. from academic 
laboratories) following good scientific principles in design, conduct and reporting and 
employing appropriate statistics, should be judged on their scientific merit and not 
automatically considered of lower quality to a TG conducted by a GLP accredited facility. 
In the frame of this screening methodology a limited WoE analysis was carried out, while 
applying the decision-tree (figure 8), in order to find the right balance between a fast 
screening of substances (due to time constraints) and the need to evaluate all available 
information. 
Studies considered reliable and scientifically sound by EU regulatory bodies within the 
consulted regulatory assessment reports were also considered reliable within the context 
of this screening methodology. Hence, the critical effect(s), target organ(s) and 
tissues(s) identified, the dose-response relationships and NOAEL(s)/NOEC(s) and 
LOAEL(s)/LOEC(s) for the critical effects were adopted for this screening. Considering 
time-constraints, the study quality of the scientific data available in the open literature, 
which had not been independently evaluated by a regulatory body, could only be 
assessed to a limited extent. Thus, all peer reviewed studies used for data collection 
were considered reliable by default. However, the results of poorly presented papers 
were discounted or given a lower weight of evidence. 
In cases where, for the same effect, contrasting evidence was available from different 
studies on the same chemical (e.g. one study observing decreased organ weight and 
another study observing an increase), expert judgment was used to reach an overall 
conclusion.  
Lastly, in case of conflicting evaluations of substance categorisation (e.g. different views 
between experts), a conservative worst-case approach was followed to decide on the 
categorisation of a substance. For this screening methodology, the worst-case approach 
was defined as placing the substance in the higher category (e.g. Cat I instead of Cat II) 
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A more detailed description of the criteria used for the limited WoE analysis applied in 
the context of this screening methodology, as developed with the contractor during the 
screening, is given below: 
1. Effects that are considered to be secondary to general systemic toxicity rather than 
specific to EATS pathways, were not considered relevant to inform on ED and 
therefore were not used for substance categorisation. 
2. Reproducibility of the effects was evaluated by observing if relevant effects (those 
in groups A to D from previous section 4.2.1) are observed across different studies, 
performed under similar experimental conditions. 
3. When the same adverse effect (measured in both sub-chronic and chronic studies) 
was observed only in sub-chronic studies (e.g. 13-week) and not in any of the 
available chronic studies (e.g. 52-week or 104-week) conducted in the same 
species, using the same route of administration and relevant doses, this effect was 
disregarded or at least considered as weak evidence. In other words, these effects 
were not considered reproducible. 
4. Consistency of the effects was assessed by evaluating if changes in the same effect 
were reported by different studies, if performed under similar experimental 
conditions, and followed the same direction (e.g. all studies observing increase of 
an organ weight). 
5. In vivo mechanistic data were considered to provide stronger evidence than in vitro 
studies, in the identification of an endocrine-related MoA (see also section 4.2). 
6. Plausible link was assessed by evaluating if information from mechanistic effects 
(group A and B) is biologically and mechanistically linked to the relevant adverse 
effect(s) (group C and D). 
7. Where relevant, proposed Adverse Outcome Pathways (AOPs) in the OECD AOP 
Knowledge Base29 were used to support a plausible link between the available 
mechanistic data and the adverse effects observed e.g.: 
 Androgen receptor agonism leading to reproductive dysfunction 
 Aromatase inhibition leading to reproductive dysfunction (in fish) 
 Estrogen receptor antagonism leading to reproductive dysfunction  
 PPARα activation in utero leading to impaired fertility in males 
 PPARγ activation leading to impaired fertility in adult females 
 Xenobiotic induced inhibition of thyroperoxidase and subsequent adverse 
neurodevelopmental outcomes in mammals  
8. Histopathological findings in rat thyroid and increased thyroid weight in presence of 
liver histopathology (including liver enzyme induction) were attributed to a liver-
mediated mechanism not considered to be ED-mediated. Since in the frame of this 
screening methodology enhancement of the metabolism and excretion of thyroid 
hormones by the liver was not considered as an endocrine MoA, such effects were 
not considered relevant to conclude on ED. The same reasoning was applied to 
effects on sex steroid hormones observed together with liver enzyme elevation.  
9. The organ weight values were reported, if available, as both absolute and relative 
weights (organ-to-body-weight ratios). However, only absolute testis weight was 
used for the evaluation since testis weight, like brain weight, is normally conserved 
despite body weight loss (Holson et al., 2011). Also, the evaluation was based on 
                                           
29 http://aopkb.org/ 
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the principle that organ-to-body weight ratio is predictive for evaluating liver and 
thyroid gland weights, and organ-to-brain weight ratio is predictive for evaluating 
ovary and adrenal gland weights (Bailey et al., 2004). 
10. A rather restrictive approach was followed for the evaluation of adrenal effects. An 
increase of adrenal gland weight and hypertrophy of the adrenal cortex are often 
altered in response to subacute and chronic stress. In toxicity studies where there 
is an increase in adrenal gland weights, it is important to differentiate adrenal 
gland hypertrophy due to stress from degenerative changes of the adrenal cortex 
(cellular hypertrophy and vacuolation) due to disruption of steroidogenesis (Everds 
et al., 2013). Therefore, particular emphasis was given to degenerative effects on 
adrenal gland, whilst changes in adrenal weights were disregarded or at least 
considered of low weight of evidence. Moreover, those effects observed in the 
absence of others from different endocrine organs or at high dose levels 
accompanied by generalised toxicity were in most cases disregarded in the 
evaluation. 
11. For vertebrate wildlife evaluation, only the adverse effects that are considered to 
be population relevant were taken into account for the categorisation. Considering 
studies in mammals, these effects include (but are not limited to) the following: 
effects on reproductive organs (ovaries, testis, etc.), developmental effects (litter 
size, litter weight, sex ratio, teratological effects, etc.), reproductive effects 
(abortions, pre- and post-implantation losses, gestation length, embryo/fetal 
viability etc.), effects on survival, sexual maturity, etc. 
12. Since it is scientifically accepted that the thyroid dysfunction can adversely affect 
reproduction and development, for the purpose of this screening methodology, 
thyroid effects in mammalian studies were considered to be population relevant 
only when they were accompanied by reproductive/developmental effects in the 
same species.  
13. In case of substances showing reproductive and/or developmental adverse effects 
but not classified as "Repr. Cat. 2 or 1B or 1A" (see CLP Regulation), these effects 
were considered in most cases to be secondary to maternal toxicity and were 
therefore not used in the evaluation/categorisation procedure. However, in some 
cases severe adverse effects on pup/foetus (e.g. resorptions, malformations such 
as hydrocephaly, reduced pup/foetal viability or total litter loss) although observed 
at maternally toxic doses, might not be exclusively attributable to maternal toxicity 
and therefore would not necessarily be disregarded. 
14. In case of substances showing reproductive and/or developmental adverse effects 
and classified as "Repr. Cat. 2 or 1B or 1A", effects were used even if observed in 
the presence of maternal toxicity since according to the criteria in the CLP 
Regulation, a substance is classified as toxic for reproduction, only when the 
reproductive/developmental adverse effects are considered not to be a secondary 
non-specific consequence of maternal/parental toxicity. 
15. During the evaluation procedure, tumours in endocrine organs were considered as 
"EATS specific adversity" to be consistent with the consideration of 
histopathological findings in the same organs. This approach overrides the general 
approach of classifying tumours as "Non-specific adversity (may or may not be 
indicative of EATS)", by considering them as EATS specific when occurring in an 
endocrine organ. 
16. In cases where the only relevant adverse and/or mechanistic effect/s was observed 
in a unique study in one species and there was no study of longer duration with the 
same species available (e.g. 2-year rat or 52-week dog study) or no other study of 
the same type of investigation (e.g. a unique multigenerational reproductive study 
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in rat), these effects were not disregarded, since in case of limited evidence a 
worst case approach was generally followed.  
17. The weight of evidence approach applied for the observed adversity was also 
applied for the available in vitro/in vivo mechanistic data. If an effect was observed 
only in one mechanistic study, but it was the only mechanistic study available, then 
it was not disregarded in the framework of this screening methodology, where in 
case of limited evidence a worst case approach was generally followed. Where 
there were more than one in vivo or in vitro mechanistic studies reported but with 
different effect direction (e.g. increase/decrease), then the evidence was 
considered equivocal and not used in the evaluation process. 
18. The potency of the available in vitro mechanistic data was taken into consideration 
for the evaluation/categorisation procedure and for the possibility to establish a 
plausible link between them and the adverse effects observed (e.g. in case the only 
in vitro mechanistic data available was a signal of low potency in an agonist assay, 
then this information was disregarded or at least considered as weak evidence for 
a plausible link). 
It should be mentioned that when applying the decision tree for each substance (figure 
9) under options 2 and 3, the WoE of the observed types of adversity and endocrine MoA 
was taken into account for each step followed. When the WoE of the observed effects 
was considered inadequate the path followed was similar to cases where no effects were 
observed. 
4.4 Categorisation under option 4 
Option 4 of the Roadmap applies the IPCS/WHO definition with inclusion of potency as 
an element of hazard characterisation. Potency depends not only on the endpoint but 
also, on the dose, on the duration and timing of exposure (EFSA, 2013). 
Option 4 applies only to those substances that are categorised as ED under option 2 or 
ED Cat I under option 3. For categorising a substance under option 4, a trigger cut-off 
value was used. Although the application of a cut-off based on potency for endocrine 
disrupting substances is widely debated (Kortenkamp et al., 2011; JRC, 2013), potency-
based cut-off values were taken from the DE-UK joint position paper which proposed to 
use the Specific Target Organ Toxicity - Repeated Exposure (STOT-RE) Cat 1 trigger 
values (from CLP Regulation; ECHA, 2015) (see Table 3). The following decision tree was 
used to categorise substances under option 4 by using these defined cut-off values 
(Figure 9). 
 
 
Figure 9. Decision tree leading to the different ED classifications according to option 4. 
 
Table 3 shows the potency-based STOT-RE Cat 1 trigger values for different routes of 
exposure that were used as cut-off values in this screening methodology. 
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Table 3. Guidance values for STOT-RE Cat I, based on a 90-day rat toxicity study. 
Route of exposure STOT-RE Cat 1 
Oral (rat) 10 mg/kg bw/day 
Dermal (rat or rabbit) 20 mg/kg bw/day 
Inhalation (rat) gas 50 ppmV/6h/day 
Inhalation (rat) vapour 0.2 mg/l/6h/day 
Inhalation (rat) (dust/mist/fume) 0.02 mg/l/6h/day 
 
The STOT-RE Cat 1 trigger values presented in Table 3 refer to effects seen in a 
standard 90-day rat toxicity study. They can be used as a basis to extrapolate equivalent 
guidance values for toxicity studies of longer or shorter duration. In particular, 
dose/exposure time extrapolation can be conducted by using an approach similar to 
Haber’s rule for inhalation. This rule states essentially that the effective dose is directly 
proportional to the exposure concentration and the duration of exposure. This leads to: 
e.g. an increase by a factor of 3 of the guidance values reported in Table 3 for a 28-day 
study; or a decrease by a factor of 8 of the guidance values for a 2-year study. Based on 
the approach followed by the RAC, similar extrapolation factors for rat, mouse and dog 
studies were used30. 
Having used such extrapolations, substances categorised as potential ED under "Option 
2" or Cat I under "Option 3" on the basis of mammalian data remain categorised as 
potential EDs for humans under "Option 4" if the effect used for the plausible link was 
observed at dose levels equal to or below the adjusted potency cut-off value. When the 
effect used for the plausible link was observed at dose levels above the adjusted potency 
cut-off value the substance was categorised as "unclassified". 
For evaluation of vertebrate wildlife (ecotoxicological assessment), substances 
categorised as potential ED under "Option 2" or Cat I under "Option 3" primarily on the 
basis of non-mammalian data (avian, fish, amphibian), were also categorised as 
potential ED under "Option 4" by applying a virtual very high potency cut-off value to the 
non-mammalian data. If the categorisation under "Option 2" and "Option 3" were 
established on the basis of mammalian data only, then the same cut-off values as used 
in the human health evaluation were used under "Option 4" for vertebrate wildlife. 
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5 Summary and conclusions 
This screening methodology was developed to assess, in a limited amount of time, the 
potential endocrine disrupting properties of approximately 600 substances. The 
substances were selected from the total lists of substances subject to different pieces of 
EU legislation related to management of risks to human health and environment, 
including the PPPR, BPR, REACH, CPR and substances subject to the WFD. In developing 
this screening methodology, it was foreseen that the results for pesticide and biocidal 
active substances would serve as an input to the assessment and comparison of the 
impacts of the different policy options on substances falling under the PPPR and the BPR. 
Bearing in mind the time constraints on the study, the methodology was designed to be 
feasible, scientifically robust and transparent, and to allow traceability of data and 
conclusions. It was necessary to limit the screening, as described above, to the MoA and 
adverse effects that are better understood, for which there exist relevant TGs, and for 
which guidance is available on the interpretation of relevance of observed effects to an 
endocrine disrupting MoA. In practice, this meant that the focus was on the Estrogenic, 
Androgenic, Steroidogenesis and Thyroid (EATS) pathways of the endocrine system. The 
OECD GD 150 was used as basis for selection of endpoints, for interpretation of 
test/assay results and for supporting the establishment of a possible link between the 
mode(s) of action and the adverse effect(s). 
Every effort was made to codify the data collection and evaluation process, and 
document all assumptions made, while recognising that any chemical assessment 
inevitably involves a degree of expert judgement that cannot be codified. As a 
consequence of the constraints of this study, which was designed to support an IA 
carried out in a limited amount of time, the screening methodology is neither equivalent 
to nor intended to replace an in-depth assessment process, and the results obtained are 
not intended to pre-empt in any way the formal regulatory conclusions that may 
eventually be made under different pieces of EU legislation. 
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Appendix A. Criteria used for substance selection 
Substances to be screened were selected according to the criteria described in the 
document "Selection of chemical substances to be screened in the context of the IA on 
criteria to identify ED" published on the DG SANTE website 
(http://ec.europa.eu/health/endocrine_disruptors/docs/impactassessment_chemicalsubs
tancesselection_en.pdf). The following rationale was used: 
 CHEMICAL SUBSTANCES REGULATED UNDER THE PLANT PROTECTION 
PRODUCTS REGULATION (PPPR) AND THE BIOCIDAL PRODUCTS 
REGULATION (BPR)  
All relevant chemicals approved by 11 May 2015 at European level to be used in 
plant protection products and biocidal products were considered as a starting point. 
The screening was then focused by excluding those substances that are considered 
to be out of scope. The stepwise rationale followed for excluding active substances 
from the screening is: 
1) Microorganisms (living organisms, no chemical substances). 
2) Basic substances, defined in Article 23 of Regulation (EC) No 1107/2009 as 
being substances of no concern and no inherent capacity to cause endocrine 
disrupting effects, and where the approval procedures follow particular 
rules. 
3) Low risk substances, defined in Annex II to Regulation (EC) 1107/2009 as, 
among others properties, not deemed to be an endocrine disruptor. 
4) Natural extracts, mixtures, or repellents 
5) Attractants (pheromones) or plant hormones 
6) Others (e.g. inert substances, salts, acids) 
Following this rationale, 324 substances falling under the PPPR and 95 substances falling 
under the BPR were selected. Among the 95 BPs there are also some chemicals not yet 
approved but where the corresponding opinions were already adopted by the Biocidal 
Products Committee of the European Chemical Agency (ECHA). 23 PPPs and 3 BPs were 
not selected following this rationale but appear on the list because they were substances 
screened during the earlier phase of the project. 
 CHEMICAL SUBSTANCES REGULATED UNDER THE REACH REGULATION 
Substances were selected for the screening exercise according to the following 
stepwise rationale: 
1) All substances on the Candidate List already identified as Substances of 
Very High Concern (SVHC) because of ED concerns under Art. 57(f) 
2) All substances for which an SVHC opinion on the identification of the 
substance as SVHC due to its endocrine disrupting properties was provided 
by the ECHA Member State Committee ; 
3) All substances on the Candidate list identified as SVHC because of 
reproductive toxicity 1A/1B; 
4) All substances listed in Annex XVII for restrictions due to an ED concern or 
because of having a harmonised classification as toxic for reproduction 
1A/1B; 
5) All substances placed on the community rolling action plan (CoRAP) due to 
ED concern; 
 
Following this procedure, 149 REACH chemical substances were selected. 
Furthermore, 52 substances registered under REACH also appear on the list of 
screened chemicals but were selected following the rationales applied for other 
legislative frameworks (i.e. they are either PPPs/BPs or substances used in 
cosmetic products) or because they were substances screened during the earlier 
phase of the project. 
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 CHEMICAL SUBSTANCES REGULATED UNDER THE COSMETIC PRODUCTS 
REGULATION (CPR) Substances used in cosmetic products were selected based 
on the following criteria: 
1) Substances for which an opinion of the Scientific Committee on Consumer 
Safety (SCCS) was provided, which contained a discussion but not 
necessarily a conclusion on their endocrine disrupting potential; 
2) Substances for which an SCCS opinion was provided due to the potential or 
de facto classification as carcinogenic, mutagenic, or toxic for reproduction 
(CMR)1A/1B or CMR2 under the Classification, Labelling and Packaging 
(CLP) Regulation; 
3) Substances not classified as CMR but for which SCCS expressed some 
concern on toxicity endpoints; 
4) Substances for which concern was raised by stakeholders / Member States 
on potential endocrine disrupting properties; 
Following this procedure, 45 chemical substances falling under the CPR were 
selected. A further 6 substances falling under the CPR also appear on the list of 
screened chemicals because they were selected following the rationales applied for 
other legislative frameworks (i.e. they are either PPPs /BPs or REACH substances.) 
 
 CHEMICAL SUBSTANCES REGULATED UNDER THE WATER FRAMEWORK 
DIRECTIVE (WFD)  
For the WFD, no specific selection criteria were applied to identify substances for the 
screening. However, some of the substances on the screening list, selected following the 
rationales applied for other legislative frameworks (i.e. PPPs/BPs, Cosmetics or REACH), 
are listed individually or fall under a group (e.g. lead and its compounds) in the list of 
priority substances under the WFD. 
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Appendix B. Policy options defined in the Commission 
Roadmap 
The following text is copied from the Roadmap (http://ec.europa.eu/smart-
regulation/impact/planned_ia/docs/2014_env_009_endocrine_disruptors_en.pdf). 
Option 1: No policy change (baseline). No criteria are specified. The interim criteria set 
in the BPR and the PPPR could continue to apply. 
Option 2: IPCS/WHO definition to identify endocrine disruptors (hazard identification).  
Endocrine disruptors are identified as: 
a) Substances which are:  
i) known or presumed to have caused endocrine-mediated adverse effects in 
humans or population-relevant endocrine-mediated adverse effects in animal 
species living in the environment or 
ii)  where there is evidence from experimental studies (in vivo), possibly 
supported with other information (e.g. (Q)SAR, analogue and category approaches) 
to provide a strong presumption that the substance has the capacity to cause endocrine-
mediated adverse effects in humans or population-relevant endocrine-mediated adverse 
effects on animal species living in the environment; 
b) The experimental studies used to determine if a substance is an endocrine disruptor 
shall provide clear evidence of endocrine-mediated adverse effects in the absence of 
other toxic effects, or if occurring together with other toxic effects, the endocrine-
mediated adverse effects should not be a non-specific secondary consequence of 
other toxic effects; 
c) An adverse effects is a change in the morphology, physiology, growth, development, 
reproduction, or, life span of an organism, system, or (sub)population that results in 
an impairment of functional capacity, an impairment of the capacity to compensate 
for additional stress, or an increase in susceptibility to other influences, as stated in 
(IPCS/WHO; 2002); 
d) Where there is (e.g. mechanistic) information demonstrating that the effects are 
clearly not relevant for humans and not relevant at population level to animal species 
living in the environment, then the substance should not be considered an endocrine 
disruptor; 
e) The identification shall follow a step by step procedure as follows: 
i) gather all available data; 
ii) assess the data quality, reliability, reproducibility and consistency; 
iii) consider adversity and MoA together in a weight of evidence approach based 
on expert judgement 
iv) evaluate whether endocrine disruption is due to a specific endocrine-mediated 
MoA and not to a non-specific secondary consequences of other toxic effects; 
v) evaluate human and wildlife relevance; 
vi) Final (eco)toxicological evaluation indicating, where possible, whether the 
adverse effect is in relation to human health or environment (vertebrates 
and/or invertebrate populations), and where possible which are the axes or 
mechanisms concerned (e.g. estrogenic, androgenic, thyroid and/or 
steroidogenic axes).  
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Option 3: IPCS/WHO definition to identify endocrine disruptors and introduction of 
additional categories based on the different strength of evidence for fulfilling the 
IPCS/WHO definition.  
Category I: endocrine disruptors (as defined in 2a-2d)  
Category II: suspected endocrine disruptors  
a) Substances where there is some evidence for endocrine-mediated adverse effects 
from humans, animal species living in the environment or from experimental 
studies, but where the evidence is not sufficiently strong to place the substance 
in Category I. If, for example, limitations in the study (or studies) make the 
quality of evidence less convincing, Category II could be more appropriate. 
b) Endocrine-mediated adverse effects should be observed in the absence of other 
toxic effects, or if occurring together with other toxic effects, the endocrine-
mediated adverse effects should not be a non-specific secondary consequence of 
other toxic effects; 
c) the points c) and d) for Category I remaining valid as well.  
Category III: endocrine active substances  
a) Substances for which there is some in vitro or in vivo evidence indicating a 
potential for endocrine disruption mediated adverse effects in intact organisms 
and where the evidence is not sufficiently convincing to place the substance in 
Category I or II.  
The allocation to categories shall follow a step by step procedure as follows:  
i) gather all available data; 
ii) assess the data quality, reliability, reproducibility and consistency; 
iii) consider adversity and MoA together in a weight of evidence approach based 
on expert judgement 
iv) evaluate whether endocrine disruption is due to a specific endocrine-mediated 
MoA and not to a non-specific secondary consequences of other toxic effects; 
v) evaluate human and wildlife relevance; 
vi) final (eco)toxicological evaluation and decision on categorisation indicating, 
where possible, for Categories I and II whether the adverse effect is in relation 
to human health or environment (vertebrates and/or invertebrate populations), 
and where possible which are the axes or mechanisms concerned (e.g. 
oestrogenic, androgenic, thyroid and/or steroidogenic axes).  
Option 4: IPCS/WHO definition to identify endocrine disruptors and inclusion of potency 
as element of hazard characterisation (hazard identification and characterisation). 
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Appendix C. Selection of assays for the screening 
methodology 
The selection of tests and assays considered for this screening methodology. The 
selection was based on the OECD GD 150, with additional in vitro assays selected from 
the US EPA ToxCast program. Rotroff et al. (2013) was used as further guidance to 
assist with the selection of relevant assays. As explained in section 3.1.1.2 the ToxCast 
ER prediction model (Browne et al., 2015) was used, when available, instead of all 
ToxCast individual assays related to the estrogen receptor. 
 
Table C1. In vitro assays considered for the screening methodology, selected from the OECD GD 150. 
  US EPA OECD 
Assay Pathway Guideline 
(OPPTS) 
Tier Guideline CF level 
ER Binding Assay Estrogen 890.1250 1 - 2 
Estrogen receptor transactivation 
assay 
Estrogen   TG 455 
TG 457 
2 
AR Binding Assay Androgen 890.1150 1 - 2 
H295R Steroidogenesis Assay Steroidogenesis 890.1550 1 TG 456 2 
Aromatase Assay Steroidogenesis 890.1200 1 - 2 
MCF-7 proliferation assays Estrogen     
 
Non-standard or guideline in vitro methods with comparable endpoints published in 
scientific literature were also included, e.g. specific reporter gene assays, proliferation 
assays and binding assays. 
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Table C2. Additional in vitro assays selected from ToxCast31. 
Assay Pathway     
ACEA_T47D_80h Estrogen receptor     
ATG_ERa_TRANS Estrogen receptor     
ATG_ERE_CIS Estrogen receptor     
ATG_ERRa_TRANS Estrogen receptor     
ATG_ERRg_TRANS Estrogen receptor     
NVS_NR_bER Estrogen receptor     
NVS_NR_hER Estrogen receptor     
NVS_NR_mERa Estrogen receptor     
OT_ERa_ERb_1440_agonist Estrogen receptor     
OT_ERaERa_1440_agonist Estrogen receptor     
OT_ERbERb_1440_agonist Estrogen receptor     
OT_ER_ERaERa_0480 Estrogen receptor     
OT_ER_ERaERb_0480 Estrogen receptor     
OT_ER_ERbERb_0480 Estrogen receptor     
OT_ERa_ERE_LUC_Agonist_1440 Estrogen receptor     
OT_ERa_ERE_LUC_Antagonist_1440 Estrogen receptor     
OT_ERa_GFPERaERE_0120 Estrogen receptor     
OT_ERa_GFPERaERE_0480 Estrogen receptor     
OT_ERb_ERE_LUC_Antagonist_1440 Estrogen receptor     
ATG_AR_TRANS Androgen receptor     
NVS_NR_hAR Androgen receptor     
NVS_NR_rAR Androgen receptor     
OT_AR_ARE_LUC_Agonist_1440 Androgen receptor     
OT_AR_ARSRC1_0480 Androgen receptor     
OT_AR_ARSRC1_0960 Androgen receptor     
NVS_NR_hTRa Thyroid receptor     
NVS_ADME_hCYP19A1 Steroidogenesis     
 
                                           
31 ToxCast data from 2014. 
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Table C3. Mammalian standard methods considered for the screening methodology. 
  US EPA OECD 
Assay Species Guideline 
(OPPTS) 
Tier Guideline CF level 
Uterotrophic Bioassay in Rodents 
(UT Assay) 
Rodents  1 TG 440 3 
Hershberger Bioassay in Rats  
(H Assay) 
Rodents  1 TG 441 3 
Male pubertal assay  
(PP Male Assay) 
Rodents 890.1500 1  4 
Female pubertal assay  
(PP Female Assay) 
Rodents 890.1450 1  4 
Adult Male Assay  
(=15 Day Adult Male assay) 
Rat    4 
Repeated Dose 28-Day Oral 
Toxicity Study in Rodents 
Rodents 870.3050 - TG 407 4 
One-Generation Reproduction 
Toxicity Study 
Rodents  - TG 415 4 
Extended One-Generation 
Reproductive Toxicity Study 
Rodents  - TG 443 5 
Repeated Dose 90-Day Oral 
Toxicity Study 
Rat 870.3100 - TG 408 4 
Repeated Dose 90-Day Oral 
Toxicity Study in Non-Rodents 
Dog 870.3150 - TG 409  
Reproduction/developmental 
toxicity screening test 
Rat 870.3550  TG 421 4 
Combined 28-Day Reproductive 
Screening Tests 
Rat   TG 422 4 
Two-Generation Reproduction 
Toxicity Study 
Rodents 870.3800 2 TG 416 5 
Combined Chronic 
Toxicity/Carcinogenicity Studies 
Rat 870.4300 - TG 451-3 4 
 
Non-standard methods with comparable endpoints (e.g. in vivo studies specifically 
performed to detect endocrine effects) published in scientific literature were also 
included.  
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Table C4. Wildlife standard methods considered for the screening methodology. 
  US EPA OECD 
Assay Species Guideline 
(OPPTS)* 
EDSP 
Tier 
Guideline CF level 
Amphibian Metamorphosis 
Assay (AMA) 
Xenopus laevis  1 TG 231 Level 3 
Fish Short Term Reproduction 
Assay (FSTRA) 
Fathead minnow, 
Japanese Medaka, 
Zebrafish 
 1 TG 229 Level 3 
Androgenised Female 
Stickleback Screen (AFSS) 
Three-spined 
stickleback  
  GD 140 Level 3 
Fish Sexual Development Test 
(FSDT) 
Three-spined 
stickleback, Japanese 
Medaka, Zebrafish 
 - TG 234 Level 4 
21-Day Fish Assay Fathead minnow, 
Japanese Medaka, 
Zebrafish 
 1 TG 230 Level 3 
Avian Reproduction Test Mallard duck 
Bobwhite quail 
Japanese quail 
  TG 206 Level 4 
Fish Lifecycle Toxicity Test 
(FLCTT) 
Fathead minnow or 
sheepshead minnow 
(marine) 
850.1500 2  Level 5 
Larval Amphibian Growth and 
Development Assay (LAGDA) 
Xenopus laevis Draft 
(December 
2014) 
  Level 4 
Medaka Extended One 
Generation Reproduction Test 
(MEOGRT) 
Japanese Medaka Draft 
(December 
2014) 
  Level 5 
Avian Two-Generation Test 
(ATGT) 
Japanese Quail 890.2100    
*
 US EPA Office of Prevention, Pesticides and Toxic Substances 
Non-standard methods with comparable endpoints (e.g. in vivo studies specifically 
performed to detect endocrine effects) published in scientific literature were also 
included. 
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Appendix D. List of endpoints considered for the screening 
methodology 
List of endpoints and their classification from the tests listed in Appendix C. 
 
Table D1. In vitro mechanistic endpoints 
Estrogen receptor Estradiol synthesis 
Estrogen related receptor Testosterone synthesis 
Androgen receptor Cellular proliferation 
CYP19 Thyroid receptor 
 Transthyretin (TTR) 
 
Table D2. Mammalian in vivo effects – mechanistic 
Cowper's glands weight (Hershberger) Thyroid histopathology (Hershberger) 
Glans penis weight (Hershberger) Uterus histopathology (UT assay) 
LABC weight (Hershberger) Testosterone level 
Prostate weight (Hershberger) Estradiol level 
Seminal vesicles weight (Hershberger) Thyroid stimulating hormone (TSH) level 
Uterus weight (UT assay) T3 and T4 level 
Keratinisation and cornification of vagina (UT assay) Luteinizing Hormone (LH) level 
Proliferation of endometrial epithelium (UT assay) Follicle Stimulating Hormone (FSH) level 
 
Table D3. Mammalian in vivo effects - EATS specific 
Accessory sex glands weight Keratinisation and cornification of vagina 
Genital abnormalities Male mammary gland histopathology 
Coagulating gland weight Mammary gland histopathology 
Cervix weight Ovary histopathology 
Cowper's glands weight Oviduct histopathology 
Epididymis weight Penis histopathology 
Glans penis weight Proliferation of endometrial epithelium 
LABC weight Prostate histopathology 
Mammary gland weight Seminal vesicles histopathology 
Ovary weight Testis histopathology 
Prostate weight Thyroid histopathology 
Seminal vesicles weight Uterus histopathology 
Testis weight Vagina histopathology 
Thyroid weight Vaginal smears 
Uterus weight Age at first estrus 
Accessory sex organs histopathology Age at preputial separation 
Ano-Genital distance Age at vaginal opening 
Cervix histopathology Estrus cyclicity 
Coagulating gland histopathology Sperm morphology 
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Colloid area Sperm motility 
Cowper's glands histopathology Sperm numbers 
Epididymis histopathology Steroidogenesis (genes/enzyme changes) 
Female mammary gland histopathology Nipple Development 
Follicular cell height  
 
Table D4. Mammalian in vivo effects - non-specific adversity (may or may not be indicative of EATS) 
Pup mortality Litter viability 
Litter/pup weight Number of implantations, corpora lutea 
Adrenals weight Number of live births 
Pituitary weight Number of ovarian follicles 
Placental weight Post implantation loss 
Vagina weight Pre implantation loss 
Adrenals histopathology Pup survival index 
Pituitary histopathology Reproduction 
Placenta histopathology Time to mating 
Birth index Resorptions 
Dystocia Live fetus 
Fertility Fetal development 
Gestational interval Fetal mortality 
Gestation length Fetal weight 
Gestation Index Maternal wastage 
Intercurrent deaths Aborted 
Lactation index Tumour types* 
Litter size Pup development 
* If tumour of endocrine organ, considered to be EATS specific 
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Table D5. Mammalian in vivo effects - general adversity 
Food consumption Kidney weight 
Body weight Brain weight 
Mortality Lung weight 
Maternal mortality Spleen weight 
Systemic toxicity Liver histopathology 
Growth Kidney histopathology 
Haematological parameters Brain histopathology 
Liver weight Lung histopathology 
 Spleen histopathology 
 
Table D6. Fish in vivo effects – mechanistic. 
Male 2nd sex characteristics in females Levels of thyroid hormones 
Male 2nd sex characteristics in males Spiggin 
Vitellogenin (VTG) in females Testosterone level 
Vitellogenin (VTG) in males Estradiol level 
Vitellogenin (VTG) in males and females T3 and T4 level 
 
Table D7. Fish in vivo effects – EATS specific. 
Specific female gonad histopathology Sex ratio (Female biased, no males)  
Specific male gonad histopathology Sex ratio (Male biased)  
Sex ratio in fish Sex ratio (Male biased, undifferentiated)  
Sex ratio (Female biased)  Gonado-somatic index 
Sex ratio (Female biased, intersex)  
 
 
Table D8. Fish in vivo effects – non-specific adversity (may or may not be indicative of EATS) 
Behaviour Fertility 
Length Time to maturity (time to first spawn) 
Abnormal morphology and appearance Reproduction (fecundity, fertility) 
Gross morphology Fecundity 
Survival of embryos Hatching success 
Gonad  
 
Table D9. Fish in vivo effects – general adversity 
Mortality Hepatosomatic index 
Growth Liver effects 
Body weight Kidney effects 
Survival  
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Table D10. Avian in vivo effects – non-specific adversity (may or may not be indicative of EATS) 
Gross pathology Egg viability 
Hatchability Egg production 
Eggshell thickness Cracked eggs 
 
Table D11. Avian in vivo effects – general adversity 
Body weight 
 
 
Table D12. Amphibian in vivo effects – mechanistic. 
Snout-vent length Developmental stage 
Hind limb length Thyroid histopathology (amphibian) 
 
Table D13. Amphibian in vivo effects – non-specific adversity (may or may not be indicative of EATS) 
Mortality Malformations 
 
Table D14. Amphibian in vivo effects – general adversity 
Behaviour 
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